Next-Gen Graphene Biosensor Technology Enables Lab Quality Diagnostics of Infectious Diseases, Anytime, Anywhere

Using disposable cartridge and a standard cell phone, the device will provide results in minutes using easy to gather samples, e.g. nasal or saliva.

GRIP Molecular Technologies, Inc. (St. Paul, MN, USA) is developing the next-generation diagnostic technology that aims to simultaneously and accurately detect a wide variety of upper respiratory infection pathogens, including Influenza, COVID-19, RSV and other common diseases, with one sample and one test that takes minutes to perform. The GRIP platform technology eliminates the need for multi-step chemical-based sample preparation and the wires, batteries, chargers, and other equipment associated with today's diagnostic tests. The samples are gathered, immediately mixed with a solution and injected into the GRIP cartridge. When the cartridge is brought into proximity with a standard cell phone, the results are automatically displayed and can be securely transmitted to a clinician to make treatment decisions virtually. New pathogens are expected to be readily added to the panel of diseases the single-use cartridge can detect to address new disease threats.

GRIP Molecular has been accepted into Blue Knight, a joint initiative between Johnson and Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA). As part of Blue Knight, GRIP will gain access to the Johnson & Johnson Innovation ecosystem through physical residency and virtual opportunities, as well as customized programming and dedicated mentorship from BARDA and the Johnson & Johnson Family of Companies.

"GRIP is at the intersection of biology, electronics and digital health. We have synergistically assembled a variety of relatively new technologies in a unique manner to put lab-grade diagnostics literally into the hands of the end user in a way that the results can be immediately shared with others to facilitate rapid diagnosis and the application of appropriate therapy," said Edward Gillen, GRIP's CEO.

Related Links:
GRIP Molecular Technologies, Inc.